MétaCan
Menu
← Back to cohort
Record W2794241916 · doi:10.1093/ecco-jcc/jjx180.564

P437 Higher adalimumab maintenance regimens are more effective than standard maintenance doses in Crohn’s disease patients who have failed infliximab

2018· article· en· W2794241916 on OpenAlexaff
Neeraj Narula, Tomer Greener, Karen Boland, A. Hillary Steinhart, Mark S. Silverberg

Bibliographic record

VenueJournal of Crohn s and Colitis · 2018
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsMount Sinai HospitalMcMaster University
Fundersnot available
KeywordsAdalimumabMedicineInfliximabDiscontinuationRegimenMaintenance therapyInternal medicineConcomitantHazard ratioCrohn's diseaseAdverse effectProportional hazards modelRetrospective cohort studySurgeryDiseaseChemotherapyConfidence interval

Abstract

fetched live from OpenAlex

Many Crohn’s disease (CD) patients who are treated with anti-TNF therapies experience a loss of response (LOR) over time and require dose escalation. The efficacy and safety of treating CD patients with higher maintenance regimens of adalimumab following induction remains unknown. We conducted a retrospective observational study with CD patients receiving adalimumab for luminal and perianal disease between 2007 and 2017 at a tertiary care IBD centre. Patients were categorised according to their maintenance regimen; 40 mg weekly, 80 mg every other week (EOW), or greater was defined as a high dose maintenance regimen (HD) and 40 mg EOW was defined as standard regimen (SD). All patients in HD group were started on high-maintenance doses directly after induction. The primary outcome was time to treatment failure, defined as non-response, loss of response (LOR) with no benefit from dose optimisation, adverse event requiring discontinuation or surgery. Cox proportional hazards regression was performed to adjust for potential confounders. We identified 39 patients that were started on HD regimens following induction and compared them to 40 patients that received SD maintenance. All subjects had previously been exposed to infliximab. According to a Kaplan–Meier survival curve analysis, time to treatment failure was significantly longer in patients in the HD group (p = 0.0015). Figure 1 Patients on HD adalimumab had a lower hazard rate of treatment failure (HR 0.21, p = 0.0005) when compared with patients on SD, after adjusting for induction dose and concomitant immunomodulator use. There was also a trend towards reduced failure in patients using concomitant immunomodulators, when adjusted for all other covariates (HR 0.48, p = 0.06). Patients in the HD group were more likely to achieve clinical remission at 3 and 12 months (89% vs. 25%, p < 0.001 and 69% vs. 31%, p = 0.003, respectively). Patients in the SD group were more likely to require IBD-related surgery or therapy optimisation (18% vs. 3%, p = 0.03 and 55% vs. 33%, p = 0.05). No difference in adverse events was identified between the groups (31% vs. 30%, p = 0.94). Higher dose maintenance regimens were more effective than the standard adalimumab maintenance protocol with better short-term and long-term clinical outcomes.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.004
GPT teacher head0.234
Teacher spread0.229 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and Colitis→Same topicInflammatory Bowel Disease→French-language works237,207→